{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:01:08Z","timestamp":1784793668493,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04449-9","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:06:59Z","timestamp":1782814019000},"page":"2481-2493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-659X","authenticated-orcid":false,"given":"Stephanie","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5551-527X","authenticated-orcid":false,"given":"Rachel A.","family":"DiCioccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie L.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushree","family":"Datar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase D.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyesh","family":"Kukadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Hoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-7892","authenticated-orcid":false,"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-4963","authenticated-orcid":false,"given":"Jennifer L.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-3619","authenticated-orcid":false,"given":"Lindsay B.","family":"Kilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-9421","authenticated-orcid":false,"given":"Brian R.","family":"Rood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-6833","authenticated-orcid":false,"given":"Adriana","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-8351","authenticated-orcid":false,"given":"Holly J.","family":"Meany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Gilbert","family":"V\u00e9zina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-3769","authenticated-orcid":false,"given":"Conrad Russell Y.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9090","authenticated-orcid":false,"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-1135","authenticated-orcid":false,"given":"Eugene I.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"4449_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11940-013-0225-x","volume":"15","author":"JE Minturn","year":"2013","unstructured":"Minturn, J. E. & Fisher, M. J. Gliomas in children. Curr. Treat. Options Neurol. 15, 316\u2013327 (2013).","journal-title":"Curr. Treat. Options Neurol."},{"key":"4449_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100851","volume":"35","author":"C Coleman","year":"2023","unstructured":"Coleman, C. et al. Interdisciplinary care of children with diffuse midline glioma. Neoplasia 35, 100851 (2023).","journal-title":"Neoplasia"},{"key":"4449_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro. Oncol. 19, 1279\u20131280 (2017).","journal-title":"Neuro. Oncol."},{"key":"4449_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520\u2013537.e5 (2017).","journal-title":"Cancer Cell"},{"key":"4449_CR5","first-page":"18","volume":"8","author":"M Alemany","year":"2020","unstructured":"Alemany, M., Velasco, R., Sim\u00f3, M. & Bruna, J. Late effects of cancer treatment: consequences for long-term brain cancer survivors. Neurooncol. Pract. 8, 18\u201330 (2020).","journal-title":"Neurooncol. Pract."},{"key":"4449_CR6","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","volume":"30","author":"AB Hont","year":"2022","unstructured":"Hont, A. B. et al. The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease. Mol. Ther. 30, 2130\u20132152 (2022).","journal-title":"Mol. Ther."},{"key":"4449_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861\u2013868 (2025).","journal-title":"Nat. Med."},{"key":"4449_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544\u20131552 (2021).","journal-title":"Nat. Med."},{"key":"4449_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","volume":"40","author":"SS Wang","year":"2019","unstructured":"Wang, S. S., Bandopadhayay, P. & Jenkins, M. R. Towards immunotherapy for pediatric brain tumors. Trends Immunol. 40, 748\u2013761 (2019).","journal-title":"Trends Immunol."},{"key":"4449_CR10","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1200\/JCO.19.00177","volume":"37","author":"AB Hont","year":"2019","unstructured":"Hont, A. B. et al. Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J. Clin. Oncol. 37, 2349\u20132359 (2019).","journal-title":"J. Clin. Oncol."},{"key":"4449_CR11","doi-asserted-by":"crossref","unstructured":"CAR T cells infiltrate brain, target tumors. Cancer Discov. 7, 926 (2017).","DOI":"10.1158\/2159-8290.CD-NB2017-109"},{"key":"4449_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4449_CR13","first-page":"e65627","volume":"16","author":"G G","year":"2024","unstructured":"G, G. et al. Immunoexpression of survivin and P53 in the histological subtypes of medulloblastoma: a cross-sectional observational study. Cureus 16, e65627 (2024).","journal-title":"Cureus"},{"key":"4449_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fonc.2020.01188","volume":"10","author":"Y Hashii","year":"2020","unstructured":"Hashii, Y. et al. Encouraging clinical evolution of a pediatric patient with relapsed diffuse midline glioma who underwent WT1-targeting immunotherapy: a case report and literature review. Front. Oncol. 10, 1188 (2020).","journal-title":"Front. Oncol."},{"key":"4449_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jnen\/nlz021","volume":"78","author":"S Lee","year":"2019","unstructured":"Lee, S. et al. Differential expression of Wilms\u2019 tumor protein in diffuse intrinsic pontine glioma. J. Neuropathol. Exp. Neurol. 78, 380\u2013388 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"4449_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/S0004-282X2011000100003","volume":"69","author":"TM Vulcani-Freitas","year":"2011","unstructured":"Vulcani-Freitas, T. M., Saba-Silva, N., Cappellano, A., Cavalheiro, S. & de Toledo, S. R. C. PRAME gene expression profile in medulloblastoma. Arq. Neuropsiquiatr. 69, 9\u201312 (2011).","journal-title":"Arq. Neuropsiquiatr."},{"key":"4449_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-008-9534-4","volume":"88","author":"JG Zhang","year":"2008","unstructured":"Zhang, J. G. et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J. Neurooncol. 88, 65\u201376 (2008).","journal-title":"J. Neurooncol."},{"key":"4449_CR18","doi-asserted-by":"publisher","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F. et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front. Immunol. 12, 745320 (2021).","journal-title":"Front. Immunol."},{"key":"4449_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"4449_CR20","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","volume":"6","author":"H Kinoshita","year":"2022","unstructured":"Kinoshita, H. et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 6, 2520\u20132534 (2022).","journal-title":"Blood Adv."},{"key":"4449_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/bloodadvances.2021005343","volume":"6","author":"H Dave","year":"2022","unstructured":"Dave, H. et al. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed\/refractory Hodgkin lymphoma. Blood Adv. 6, 473\u2013485 (2022).","journal-title":"Blood Adv."},{"key":"4449_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00401-021-02388-y","volume":"143","author":"C-HG Lucas","year":"2022","unstructured":"Lucas, C.-H. G. et al. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathol. 143, 109\u2013113 (2022).","journal-title":"Acta Neuropathol."},{"key":"4449_CR23","doi-asserted-by":"publisher","first-page":"vi183","DOI":"10.1093\/neuonc\/noz175.765","volume":"21","author":"J Grill","year":"2019","unstructured":"Grill, J. et al. PDCT-01. Biological medicine for diffuse intrinsic pontine gliomas eradication (BIOMEDE): results of the three-arm biomarker-driven randomized trial in the first 230 patients from Europe and Australia. Neuro. Oncol. 21, vi183 (2019).","journal-title":"Neuro. Oncol."},{"key":"4449_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"4449_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"4449_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."},{"key":"4449_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq4297","volume":"11","author":"KA Nguyen","year":"2025","unstructured":"Nguyen, K. A. et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. Sci. Adv. 11, eadq4297 (2025).","journal-title":"Sci. Adv."},{"key":"4449_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell, F., Berger, T. R. & Maus, M. V. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Medicine 3, 538\u2013564 (2022).","journal-title":"Medicine"},{"key":"4449_CR29","doi-asserted-by":"publisher","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer, J. W. & Bhattarai, N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front. Immunol. 12, 693016 (2021).","journal-title":"Front. Immunol."},{"key":"4449_CR30","doi-asserted-by":"publisher","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","volume":"19","author":"DT Peters","year":"2023","unstructured":"Peters, D. T., Savoldo, B. & Grover, N. S. Building safety into CAR-T therapy. Hum. Vaccin. Immunother. 19, 2275457 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"4449_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1215\/S1152851704001061","volume":"7","author":"DJ Brat","year":"2005","unstructured":"Brat, D. J., Bellail, A. C. & Van Meir, E. G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122\u2013133 (2005).","journal-title":"Neuro. Oncol."},{"key":"4449_CR32","doi-asserted-by":"publisher","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek, K., Horn, L. A. & Palena, C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol. Ther. 219, 107692 (2021).","journal-title":"Pharmacol. Ther."},{"key":"4449_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1387-6","volume":"10","author":"T Hasan","year":"2019","unstructured":"Hasan, T. et al. Interleukin-8\/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma. Cell Death Dis. 10, 292 (2019).","journal-title":"Cell Death Dis."},{"key":"4449_CR34","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.3390\/cancers13246251","volume":"13","author":"E Hayden","year":"2021","unstructured":"Hayden, E. et al. Therapeutic targets in diffuse midline gliomas\u2014an emerging landscape. Cancers 13, 6251 (2021).","journal-title":"Cancers"},{"key":"4449_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab072","volume":"3","author":"CB Holst","year":"2021","unstructured":"Holst, C. B. et al. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma. Neuro. Oncol. Adv. 3, vdab072 (2021).","journal-title":"Neuro. Oncol. Adv."},{"key":"4449_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J. Hematol. Oncol. 17, 31 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"4449_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccell.2023.03.004","volume":"41","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell 41, 693\u2013710.e8 (2023).","journal-title":"Cancer Cell"},{"key":"4449_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02630-8","volume":"19","author":"CJ Pachocki","year":"2022","unstructured":"Pachocki, C. J. & Hol, E. M. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. J. Neuroinflamm. 19, 276 (2022).","journal-title":"J. Neuroinflamm."},{"key":"4449_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0464-y","volume":"25","author":"I Sharma","year":"2018","unstructured":"Sharma, I., Singh, A., Siraj, F. & Saxena, S. IL-8\/CXCR1\/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma. J. Biomed. Sci. 25, 62 (2018).","journal-title":"J. Biomed. Sci."},{"key":"4449_CR40","first-page":"wuaf002","volume":"1","author":"TJM Van Den Broek","year":"2025","unstructured":"Van Den Broek, T. J. M. et al. Single-cell spatial analysis of pediatric high-grade glioma reveals a novel population of SPP1+\/GPNMB+ myeloid cells with immunosuppressive and tumor-promoting capabilities. Neurooncol. Pediatr. 1, wuaf002 (2025).","journal-title":"Neurooncol. Pediatr."},{"key":"4449_CR41","doi-asserted-by":"publisher","first-page":"e012009","DOI":"10.1136\/jitc-2025-012009","volume":"13","author":"B Van den Ende","year":"2025","unstructured":"Van den Ende, B. et al. Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges. J. Immunother. Cancer 13, e012009 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"4449_CR42","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1158\/1078-0432.CCR-22-3273","volume":"29","author":"W Yuan","year":"2023","unstructured":"Yuan, W. et al. Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages. Clin. Cancer Res. 29, 3779\u20133792 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4449_CR43","doi-asserted-by":"crossref","unstructured":"Vakilian, A. et al. CCL2\/CCR2 signaling pathway in glioblastoma multiforme. Neurochem. Int. 103, 1\u20137 (2017).","DOI":"10.1016\/j.neuint.2016.12.013"},{"key":"4449_CR44","doi-asserted-by":"publisher","first-page":"e70016","DOI":"10.1002\/cam4.70016","volume":"13","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Noninvasive prediction of CCL2 expression level in high-grade glioma patients. Cancer Med. 13, e70016 (2024).","journal-title":"Cancer Med."},{"key":"4449_CR45","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang, A. L. et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 76, 5671\u20135682 (2016).","journal-title":"Cancer Res."},{"key":"4449_CR46","doi-asserted-by":"publisher","first-page":"P72","DOI":"10.1186\/2051-1426-3-S2-P72","volume":"3","author":"AL Chang","year":"2015","unstructured":"Chang, A. L. et al. Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells. J. Immunother. Cancer 3, P72 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"4449_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-023-09674-x","volume":"24","author":"L Deng","year":"2023","unstructured":"Deng, L. et al. Predictive value of CCL2 in the prognosis and immunotherapy response of glioblastoma multiforme. BMC Genomics 24, 746 (2023).","journal-title":"BMC Genomics"},{"key":"4449_CR48","doi-asserted-by":"publisher","first-page":"eabg8139","DOI":"10.1126\/sciadv.abg8139","volume":"7","author":"C Hajal","year":"2021","unstructured":"Hajal, C. et al. The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain. Sci. Adv. 7, eabg8139 (2021).","journal-title":"Sci. Adv."},{"key":"4449_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993444","volume":"13","author":"GP Takacs","year":"2022","unstructured":"Takacs, G. P. et al. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. Front. Immunol. 13, 993444 (2022).","journal-title":"Front. Immunol."},{"key":"4449_CR50","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).","journal-title":"Front. Immunol."},{"key":"4449_CR51","doi-asserted-by":"publisher","first-page":"100","DOI":"10.56875\/2589-0646.1029","volume":"15","author":"HS Murthy","year":"2022","unstructured":"Murthy, H. S. et al. Management of CAR T-cell related toxicities: what did the learning curve teach us so far? Hematol. Oncol. Stem Cell Ther. 15, 100\u2013111 (2022).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"4449_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe2606","volume":"14","author":"AI Salter","year":"2021","unstructured":"Salter, A. I. et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci. Signal. 14, eabe2606 (2021).","journal-title":"Sci. Signal."},{"key":"4449_CR53","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"4449_CR54","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna, S. et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin. Cancer Res. 25, 5329\u20135341 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4449_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41591-025-04043-5","volume":"32","author":"BL Musher","year":"2026","unstructured":"Musher, B. L. et al. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1\/2 trial. Nat. Med. 32, 258\u2013269 (2026).","journal-title":"Nat. Med."},{"key":"4449_CR56","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","volume":"186","author":"G Dolton","year":"2023","unstructured":"Dolton, G. et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186, 3333\u20133349.e27 (2023).","journal-title":"Cell"},{"key":"4449_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00002371-200501000-00007","volume":"28","author":"J Zhou","year":"2005","unstructured":"Zhou, J., Dudley, M. E., Rosenberg, S. A. & Robbins, P. F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28, 53\u201362 (2005).","journal-title":"J. Immunother."},{"key":"4449_CR58","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","volume":"41","author":"JA Pai","year":"2023","unstructured":"Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell 41, 776\u2013790.e7 (2023).","journal-title":"Cancer Cell"},{"key":"4449_CR59","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/2767-9764.CRC-23-0424","volume":"3","author":"D Haydar","year":"2023","unstructured":"Haydar, D. et al. CAR T-cell design-dependent remodeling of the brain tumor immune microenvironment modulates tumor-associated macrophages and anti-glioma activity. Cancer Res. Commun. 3, 2430\u20132446 (2023).","journal-title":"Cancer Res. Commun."},{"key":"4449_CR60","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1073\/pnas.1614777114","volume":"114","author":"ZI Kovacs","year":"2017","unstructured":"Kovacs, Z. I. et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc. Natl Acad. Sci. USA 114, E75\u2013E84 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4449_CR61","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41551-023-01107-0","volume":"8","author":"AR Kline-Schoder","year":"2024","unstructured":"Kline-Schoder, A. R. et al. Characterization of the responses of brain macrophages to focused ultrasound-mediated blood\u2013brain barrier opening. Nat. Biomed. Eng 8, 650\u2013663 (2024).","journal-title":"Nat. Biomed. Eng"},{"key":"4449_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12987-022-00402-3","volume":"19","author":"HJ Choi","year":"2022","unstructured":"Choi, H. J. et al. The new insight into the inflammatory response following focused ultrasound-mediated blood\u2013brain barrier disruption. Fluids Barriers CNS 19, 103 (2022).","journal-title":"Fluids Barriers CNS"},{"key":"4449_CR63","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic, A. et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell 184, 2988\u20133005.e16 (2021).","journal-title":"Cell"},{"key":"4449_CR64","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10555-024-10208-4","volume":"43","author":"R Ronsley","year":"2024","unstructured":"Ronsley, R. et al. CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials. Cancer Metastasis Rev. 43, 1205\u20131216 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"4449_CR65","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"4449_CR66","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780141102","volume":"14","author":"SN Goodman","year":"1995","unstructured":"Goodman, S. N., Zahurak, M. L. & Piantadosi, S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14, 1149\u20131161 (1995).","journal-title":"Stat. Med."},{"key":"4449_CR67","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1307::AID-SIM128>3.0.CO;2-X","volume":"18","author":"JM Heyd","year":"1999","unstructured":"Heyd, J. M. & Carlin, B. P. Adaptive design improvements in the continual reassessment method for phase I studies. Stat. Med. 18, 1307\u20131321 (1999).","journal-title":"Stat. Med."},{"key":"4449_CR68","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/sim.4780131802","volume":"13","author":"EL Korn","year":"1994","unstructured":"Korn, E. L. et al. A comparison of two phase I trial designs. Stat. Med. 13, 1799\u20131806 (1994).","journal-title":"Stat. Med."},{"key":"4449_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"4449_CR70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s002800050763","volume":"41","author":"S Piantadosi","year":"1998","unstructured":"Piantadosi, S., Fisher, J. D. & Grossman, S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother. Pharmacol. 41, 429\u2013436 (1998).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4449_CR71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"4449_CR72","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1470-2045(20)30166-2","volume":"21","author":"TM Cooney","year":"2020","unstructured":"Cooney, T. M. et al. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 21, e330\u2013e336 (2020).","journal-title":"Lancet Oncol."},{"key":"4449_CR73","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","volume":"21","author":"C Erker","year":"2020","unstructured":"Erker, C. et al. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 21, e317\u2013e329 (2020).","journal-title":"Lancet Oncol."},{"key":"4449_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/neuonc\/nox087","volume":"20","author":"KE Warren","year":"2018","unstructured":"Warren, K. E. et al. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro. Oncol. 20, 13\u201323 (2018).","journal-title":"Neuro. Oncol."},{"key":"4449_CR75","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen, P. Y. et al. Response assessment in neuro-oncology clinical trials. J. Clin. Oncol. 35, 2439\u20132449 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4449_CR76","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"4449_CR77","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-13-0955","volume":"19","author":"G Weber","year":"2013","unstructured":"Weber, G. et al. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia\u2013implications for immunotherapy. Clin. Cancer Res. 19, 5079\u20135091 (2013).","journal-title":"Clin. Cancer Res."},{"key":"4449_CR78","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/leu.2013.66","volume":"27","author":"G Weber","year":"2013","unstructured":"Weber, G. et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia 27, 1538\u20131547 (2013).","journal-title":"Leukemia"},{"key":"4449_CR79","doi-asserted-by":"crossref","unstructured":"Kalyuzhny, A. E. (ed.) Handbook of ELISPOT Vol. 792 (Humana, 2012).","DOI":"10.1007\/978-1-61779-325-7"},{"key":"4449_CR80","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489\u20131501 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"4449_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","volume":"315","author":"Z Moodie","year":"2006","unstructured":"Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J. Immunol. Methods 315, 121\u2013132 (2006).","journal-title":"J. Immunol. Methods"},{"key":"4449_CR82","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.copbio.2020.07.010","volume":"65","author":"J Chiffelle","year":"2020","unstructured":"Chiffelle, J. et al. T-cell repertoire analysis and metrics of diversity and clonality. Curr. Opin. Biotechnol. 65, 284\u2013295 (2020).","journal-title":"Curr. Opin. Biotechnol."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04593-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04449-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04449-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04449-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:01:42Z","timestamp":1784790102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04449-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4449"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04449-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04593-2","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04593-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.I.H., P.J.H., L.B.K., C.M.B. and C.R.Y.C. declare the following competing interests. E.I.H. is on the MAB or has consulted for DayOne Therapeutics and Fennec Pharmaceuticals. P.J.H. is on the board of (or an advisor to) Autolomous, Cipla, Cellenkos, CARTx, MFX, March Bio and Y Innovations. L.B.K. is a consultant for Blueprint Medicine (DSMB) and Chimerix -a Jazz company (advisory board). C.M.B. is on the board of directors of Cabaletta Bio on the scientific advisory board of Minovia TX, and she has recently served on the DSMB of SOBI. C.R.Y.C., P.J.H. and C.M.B. are inventors on patent applications filed by Children\u2019s National Hospital (Children\u2019s National Medical Center) related to TAA-T therapies. These include PCT\/US2019\/033182, which covers the generation and use of T cells targeting TAAs (including PRAME, WT1 and survivin) as described in this paper. Additional patent applications related to TAA-specific T cell compositions and methods (PCT\/US2019\/028589 and PCT\/US2020\/012639) are listed as pending in public records, though the institution has instructed patent counsel to abandon PCT\/US2019\/033182 and PCT\/US2020\/012639; patent application PCT\/US2021\/035008 is a pending patent application related to TAA-T cells. These additional filings do not specifically cover the clinical study reported here. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}